Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
XRAY
BUYFLAGDENTSPLY SIRONA Inc. · Healthcare · United States · $2.6B · Avg Vol: $77M/d
DENTSPLY SIRONA has value V64 and momentum M66 with a nominal insider buy, but quality at Q42 is below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
DENTSPLY SIRONA Inc. is the world's largest manufacturer of professional dental products and technologies, offering a comprehensive portfolio including implants, imaging systems, and consumables. The company provides integrated solutions that enable dental professionals to deliver better, faster, and safer care. DENTSPLY SIRONA's broad product offering, global reach, and strong R&D capabilities underpin its market leadership in the dental industry.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.9B | 4.0B | 3.8B | 3.7B | -2.1% | 3.7B | 3.6B | 3.7B | -0.3% |
| EPS | -4.41 | -0.62 | -4.48 | -3.00 | — | -3.02 | — | — | — |
| Shares | 215.3M | 207.2M | 198.8M | 199.6M | -7.3% | 200.3M | — | — | — |
| Debt | 2.1B | 2.3B | 2.3B | 2.5B | 4.8% | 2.3B | — | — | — |
| Equity | 3.8B | 3.3B | 1.9B | 1.3B | -29.4% | — | — | — | — |
| Op CF | 517.0M | 377.0M | 461.0M | 235.0M | -23.1% | 268.0M | — | — | — |
| Inv CF | -138.0M | -89.0M | -197.0M | -132.0M | — | — | — | — | — |
| Fin CF | -329.0M | -307.0M | -302.0M | -80.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XRAY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| XRAY | DENTSPLY SIRONA Inc.(you) | $2.6B | 74 | BUY |
| LMAT | LeMaitre Vascular, Inc. | $2.2B | 76 | BUY |
| MMSI | Merit Medical Systems, Inc. | $4.4B | 79 | BUY |
| ICUI | ICU Medical, Inc. | $3.9B | 83 | STRONG BUY |
| TFX | Teleflex Incorporated | $5.8B | 69 | BUY |
| ATR | AptarGroup, Inc. | $8.4B | 74 | BUY |
| ATRC | AtriCure, Inc. | $1.8B | 55 | HOLD |
| NVST | Envista Holdings Corporation | $4.3B | 90 | STRONG BUY |
| BLFS | BioLife Solutions, Inc. | $1.5B | 56 | HOLD |
| AVTR | Avantor, Inc. | $7.8B | 64 | HOLD |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%